Literature DB >> 8902719

Autosomal dominant cerebellar ataxia type I: multimodal electrophysiological study and comparison between SCA1 and SCA2 patients.

A Perretti1, L Santoro, B Lanzillo, A Filla, G De Michele, F Barbieri, G Martino, M Ragno, S Cocozza, G Caruso.   

Abstract

A multimodal electrophysiological study was performed on 41 patients from 24 families with autosomal dominant cerebellar ataxia type I (ADCA I). Upper- and lower-limb motor evoked potentials (MEPs) to transcranial magnetic stimulation, median and tibial nerve somatosensory evoked potentials (Mn and Tn-SSEPs), orthodromic sensory (SCV) and motor conduction (MCV) velocity along median and tibial nerve, brainstem auditory evoked potentials (BAEPs), and visual evoked potentials (VEPs) were examined. Molecular analysis showed 2 SCA1 families and 2 families linked to the SCA2 locus. A sural nerve biopsy was performed in 5 patients. Brainstem damage of the auditory pathway was observed in 79% of patients examined. VEP abnormalities possibly of central origin were found in 52% of patients. MEP and SSEP abnormalities were differently distributed along the pathways examined: the longer the pathway, the higher the occurrence and severity of impairment. Peripheral dying-back neuropathy (confirmed by nerve bioptic data) was a frequent finding (56%). A progressive degenerative process involving first the longest tracts of the central motor and central and peripheral branches of somatosensory pathways is hypothesized in ADCA I. MEP abnormalities were more frequent in SCA1, and the sensory-motor neuropathy was more severe in SCA2.

Entities:  

Mesh:

Year:  1996        PMID: 8902719     DOI: 10.1016/0022-510x(96)00140-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  An electrophysiological study of visual processing in spinocerebellar ataxia type 2 (SCA2).

Authors:  Jan Kremlacek; Martin Valis; Jiri Masopust; Ales Urban; Alena Zumrova; Radomir Talab; Miroslav Kuba; Zuzana Kubova; Jana Langrova
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

2.  Peripheral Neuropathy in Spinocerebellar Ataxia Type 1, 2, 3, and 6.

Authors:  Christoph Linnemann; Sophie Tezenas du Montcel; Maryla Rakowicz; Tanja Schmitz-Hübsch; Sandra Szymanski; Jose Berciano; Bart P van de Warrenburg; Karine Pedersen; Chantal Depondt; Rafal Rola; Thomas Klockgether; Antonio García; Gurkan Mutlu; Ludger Schöls
Journal:  Cerebellum       Date:  2016-04       Impact factor: 3.847

3.  Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson's disease.

Authors:  Anna De Rosa; Sabina Pappatà; Teresa Pellegrino; Maria Fulvia De Leva; Gennaro Maddaluno; Giovanni Fiumara; Raffaella Carotenuto; Mario Petretta; Alessandro Filla; Giuseppe De Michele; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-09       Impact factor: 9.236

Review 4.  Spinocerebellar ataxia 2 (SCA2).

Authors:  Isabel Lastres-Becker; Udo Rüb; Georg Auburger
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 5.  Oxidative stress as a cofactor in spinocerebellar ataxia type 2.

Authors:  Mariela Guevara-García; Lizette Gil-del Valle; Luis Velásquez-Pérez; Julio César García-Rodríguez
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

6.  Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1.

Authors:  Sarah Stricker; Timm Oberwahrenbrock; Hanna Zimmermann; Jan Schroeter; Matthias Endres; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

7.  Multimodal evoked potentials in spinocerebellar ataxia types 1, 2, and 3.

Authors:  Vijay Chandran; Ketan Jhunjhunwala; Meera Purushottam; Sanjeev Jain; Pramod Kumar Pal
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

Review 8.  The Multiple Faces of Spinocerebellar Ataxia type 2.

Authors:  Antonella Antenora; Carlo Rinaldi; Alessandro Roca; Chiara Pane; Maria Lieto; Francesco Saccà; Silvio Peluso; Giuseppe De Michele; Alessandro Filla
Journal:  Ann Clin Transl Neurol       Date:  2017-08-10       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.